Details
Stereochemistry | ACHIRAL |
Molecular Formula | C18H18ClN3O.C4H6O4 |
Molecular Weight | 445.896 |
Optical Activity | NONE |
Defined Stereocenters | 0 / 0 |
E/Z Centers | 0 |
Charge | 0 |
SHOW SMILES / InChI
SMILES
OC(=O)CCC(O)=O.CN1CCN(CC1)C2=NC3=C(OC4=C2C=C(Cl)C=C4)C=CC=C3
InChI
InChIKey=YQZBAXDVDZTKEQ-UHFFFAOYSA-N
InChI=1S/C18H18ClN3O.C4H6O4/c1-21-8-10-22(11-9-21)18-14-12-13(19)6-7-16(14)23-17-5-3-2-4-15(17)20-18;5-3(6)1-2-4(7)8/h2-7,12H,8-11H2,1H3;1-2H2,(H,5,6)(H,7,8)
Molecular Formula | C18H18ClN3O |
Molecular Weight | 327.808 |
Charge | 0 |
Count |
|
Stereochemistry | ACHIRAL |
Additional Stereochemistry | No |
Defined Stereocenters | 0 / 0 |
E/Z Centers | 0 |
Optical Activity | NONE |
Molecular Formula | C4H6O4 |
Molecular Weight | 118.088 |
Charge | 0 |
Count |
|
Stereochemistry | ACHIRAL |
Additional Stereochemistry | No |
Defined Stereocenters | 0 / 0 |
E/Z Centers | 0 |
Optical Activity | NONE |
DescriptionCurator's Comment: Description was created based on several sources, including
https://www.ncbi.nlm.nih.gov/pubmed/25859275
Curator's Comment: Description was created based on several sources, including
https://www.ncbi.nlm.nih.gov/pubmed/25859275
Loxapine is a dibenzoxazepine tricyclic antipsychotic agent, available for oral and inhalatory administration, classified as a typical antipsychotic. Loxapine acts as an antagonist at central serotonin and dopamine receptors. Adasuve (loxapine inhalation powder) is a prescription medicine that is used to treat acute agitation in adults with schizophrenia or bipolar I disorder.
CNS Activity
Originator
Approval Year
Targets
Primary Target | Pharmacology | Condition | Potency |
---|---|---|---|
Target ID: P21728 Gene ID: 1812.0 Gene Symbol: DRD1 Target Organism: Homo sapiens (Human) |
18.0 nM [Ki] | ||
Target ID: P14416 Gene ID: 1813.0 Gene Symbol: DRD2 Target Organism: Homo sapiens (Human) |
10.0 nM [Ki] | ||
Target ID: P35462 Gene ID: 1814.0 Gene Symbol: DRD3 Target Organism: Homo sapiens (Human) |
21.0 nM [Ki] | ||
Target ID: P21917 Gene ID: 1815.0 Gene Symbol: DRD4 Target Organism: Homo sapiens (Human) |
9.0 nM [Ki] | ||
Target ID: P35367 Gene ID: 3269.0 Gene Symbol: HRH1 Target Organism: Homo sapiens (Human) |
15.0 nM [Ki] | ||
Target ID: P11229 Gene ID: 1128.0 Gene Symbol: CHRM1 Target Organism: Homo sapiens (Human) |
117.0 nM [Ki] | ||
Target ID: P08913 Gene ID: 150.0 Gene Symbol: ADRA2A Target Organism: Homo sapiens (Human) |
250.0 nM [Ki] | ||
Target ID: P28223 Gene ID: 3356.0 Gene Symbol: HTR2A Target Organism: Homo sapiens (Human) |
2.0 nM [Ki] |
Conditions
Condition | Modality | Targets | Highest Phase | Product |
---|---|---|---|---|
Primary | LOXITANE Approved UseLoxapine Capsules, USP are indicated for the treatment of schizophrenia. The efficacy of loxapine in schizophrenia was established in clinical studies which enrolled newly hospitalized and chronically hospitalized acutely ill schizophrenic patients as subjects. Launch Date1.62518401E11 |
|||
Primary | Adasuve Approved UseSchizophrenia Launch Date1.3559616E12 |
|||
Primary | Adasuve Approved UseBipolar I disorder Launch Date1.3559616E12 |
Cmax
Value | Dose | Co-administered | Analyte | Population |
---|---|---|---|---|
257 ng/mL |
10 mg single, respiratory dose: 10 mg route of administration: Respiratory experiment type: SINGLE co-administered: |
LOXAPINE plasma | Homo sapiens population: HEALTHY age: ADULT sex: UNKNOWN food status: UNKNOWN |
AUC
Value | Dose | Co-administered | Analyte | Population |
---|---|---|---|---|
188 ng × h/mL |
10 mg single, respiratory dose: 10 mg route of administration: Respiratory experiment type: SINGLE co-administered: |
LOXAPINE plasma | Homo sapiens population: HEALTHY age: ADULT sex: UNKNOWN food status: UNKNOWN |
T1/2
Value | Dose | Co-administered | Analyte | Population |
---|---|---|---|---|
7.61 h |
10 mg single, respiratory dose: 10 mg route of administration: Respiratory experiment type: SINGLE co-administered: |
LOXAPINE plasma | Homo sapiens population: HEALTHY age: ADULT sex: UNKNOWN food status: UNKNOWN |
Funbound
Value | Dose | Co-administered | Analyte | Population |
---|---|---|---|---|
3.4% |
10 mg single, respiratory dose: 10 mg route of administration: Respiratory experiment type: SINGLE co-administered: |
LOXAPINE plasma | Homo sapiens population: HEALTHY age: ADULT sex: UNKNOWN food status: UNKNOWN |
Overview
CYP3A4 | CYP2C9 | CYP2D6 | hERG |
---|---|---|---|
OverviewOther
Other Inhibitor | Other Substrate | Other Inducer |
---|---|---|
Drug as perpetrator
Target | Modality | Activity | Metabolite | Clinical evidence |
---|---|---|---|---|
Page: 66.0 |
no | |||
Page: 66.0 |
no | |||
Page: 66.0 |
no | |||
Page: 66.0 |
no | |||
Page: 66.0 |
no | |||
Page: 66.0 |
no | |||
Page: 66.0 |
no | |||
Page: 66.0 |
no | |||
Page: 66.0 |
no | |||
Page: 66.0 |
no | |||
Page: 20.0 |
yes |
Drug as victim
Target | Modality | Activity | Metabolite | Clinical evidence |
---|---|---|---|---|
Page: 63.0 |
minor | |||
Page: 20.0 |
no | no (co-administration study) Comment: ketoconazole did not affect loxapine transport Page: 20.0 |
||
Page: 20.0 |
yes | |||
Page: 10.0 |
yes | |||
Page: 10.0 |
yes | |||
Page: 20.0 |
yes | |||
Page: 20.0 |
yes | |||
Page: 10.0 |
yes | |||
Page: 20.0 |
yes |
Tox targets
Target | Modality | Activity | Metabolite | Clinical evidence |
---|---|---|---|---|
Page: 181.0 |
PubMed
Title | Date | PubMed |
---|---|---|
Inhibition of glucose transport in PC12 cells by the atypical antipsychotic drugs risperidone and clozapine, and structural analogs of clozapine. | 2001 Dec 27 |
|
Treatment of the special patient with schizophrenia. | 2001 Jun |
|
Human genetic variations in the 5HT2A receptor: a single nucleotide polymorphism identified with altered response to clozapine. | 2003 Feb |
|
In vitro human plasma leucine(5)-enkephalin degradation is inhibited by a select number of drugs with the phenothiazine molecule in their chemical structure. | 2003 Jan |
|
H1-histamine receptor affinity predicts short-term weight gain for typical and atypical antipsychotic drugs. | 2003 Mar |
|
[Survey of management methods for patients in a state of agitation at admission and emergency departments in France]. | 2003 Mar-Apr |
|
Induction of hyperglycemia in mice with atypical antipsychotic drugs that inhibit glucose uptake. | 2003 May |
|
A comparison of the effects of loxapine with ziprasidone and thioridazine on the release of dopamine and acetylcholine in the prefrontal cortex and nucleus accumbens. | 2003 May |
|
Differential effects of atypical and typical antipsychotic drugs on N-methyl-D-aspartate- and electrically evoked responses in the pyramidal cells of the rat medial prefrontal cortex. | 2003 May |
|
Effects of some antidepressant drugs on tryptaminergic responses of the rat jejunum. | 2003 Oct |
|
Simultaneous determination of four antipsychotic drugs in plasma by high-performance liquid chromatography. Application to management of acute intoxications. | 2003 Oct 5 |
|
JL 13, an atypical antipsychotic: a preclinical review. | 2003 Spring |
|
Differential inverse agonist efficacies of SB-258719, SB-258741 and SB-269970 at human recombinant serotonin 5-HT7 receptors. | 2004 Jul 14 |
|
Transient hyperproinsulinemia during treatment with clozapine and amisulpride. | 2004 Jun |
|
Treatment-refractory schizophrenia. | 2004 Mar |
|
[Agranulocytosis induced by loxapine in an elderly patient: a case study]. | 2004 Sep-Oct |
|
Atypical and typical antipsychotic drug interactions with the dopamine D2 receptor. | 2005 Feb |
|
Minimally effective doses of conventional antipsychotic medications used to treat aggression, self-injurious and destructive behaviors in mentally retarded adults. | 2005 Feb |
|
Chlorpromazine and loxapine reduce interleukin-1beta and interleukin-2 release by rat mixed glial and microglial cell cultures. | 2005 Jan |
|
Treatment of acute mania--from clinical trials to recommendations for clinical practice. | 2005 Jan |
|
Stable expression of constitutively activated mutant h5HT6 and h5HT7 serotonin receptors: inverse agonist activity of antipsychotic drugs. | 2005 May |
|
NMS after clozapine initiation. | 2005 Nov |
|
Lack of enhanced effect of antipsychotics combined with fluvoxamine on acetylcholine release in rat prefrontal cortex. | 2006 Dec |
|
Adjunctive topiramate in ultradian cycling bipolar disorder: case report with 3-year follow-up. | 2006 Jun |
|
[Clinical and socio-demographic profile of patients with schizophrenia according to the antipsychotic treatment prescribed]. | 2006 May-Jun |
|
Efficacy of typical and atypical antipsychotics for primary and comorbid anxiety symptoms or disorders: a review. | 2006 Sep |
|
Effect of loxapine on electrical brain activity, intracranial pressure, and middle cerebral artery flow velocity in traumatic brain-injured patients. | 2007 |
|
Simultaneous determination of the antipsychotic drugs levomepromazine and clozapine and their main metabolites in human plasma by a HPLC-UV method with solid-phase extraction. | 2007 Feb 1 |
|
Simultaneous analysis of classical neuroleptics, atypical antipsychotics and their metabolites in human plasma. | 2007 May |
|
Pharmacological causes of hyperprolactinemia. | 2007 Oct |
|
Analysis of the recent antipsychotic aripiprazole in human plasma by capillary electrophoresis and high-performance liquid chromatography with diode array detection. | 2008 Apr 7 |
|
The effect of antipsychotic medication on sexual function and serum prolactin levels in community-treated schizophrenic patients: results from the Schizophrenia Trial of Aripiprazole (STAR) study (NCT00237913). | 2008 Dec 22 |
|
Modifications of antiepileptic drugs for improved tolerability and efficacy. | 2008 Feb 14 |
|
Incorporating clinical guidelines through clinician decision-making. | 2008 Feb 29 |
|
Rapid liquid chromatography/tandem mass spectrometer (LCMS) method for clozapine and its metabolite N-desmethyl clozapine (norclozapine) in human serum. | 2009 |
|
Neuroanatomical, neurochemical, and neurodevelopmental basis of obsessive-compulsive symptoms in schizophrenia. | 2009 Jan |
|
Spectroscopic and electrochemical analysis of psychotropic drugs. | 2009 Jan |
|
Psychotic woman with painful abdominal distension. Life-threatening psychotropic drug-induced gastrointestinal hypomotility. | 2009 Nov |
|
Bacitracin-sensitive aminopeptidase(s) degradation of methionine(5)-enkephalin by human brain putamen and hippocampus preparations: inhibition by phenothiazine drugs. | 2009 Nov-Dec |
|
Current perspectives in the treatment of resistant schizophrenia. | 2009 Oct-Dec |
|
Beneficial effects of loxapine on agitation and breathing patterns during weaning from mechanical ventilation. | 2010 |
|
Validation of HPLC-MS/MS methods for analysis of loxapine, amoxapine, 7-OH-loxapine, 8-OH-loxapine and loxapine N-oxide in human plasma. | 2010 Dec |
|
[Catatonia in a 14 year-old girl: treatment with clorazepam and carbamazepine, a 10-year follow-up]. | 2010 Feb |
|
An overview of Indian research in schizophrenia. | 2010 Jan |
|
Simultaneous HPLC determination of 14 tricyclic antidepressants and metabolites in human plasma. | 2010 Jan |
|
Identifying unexpected therapeutic targets via chemical-protein interactome. | 2010 Mar 8 |
|
Chem2Bio2RDF: a semantic framework for linking and data mining chemogenomic and systems chemical biology data. | 2010 May 17 |
|
4-Nitro-2-phenoxy-aniline. | 2010 May 8 |
|
Olanzapine approved for the acute treatment of schizophrenia or manic/mixed episodes associated with bipolar I disorder in adolescent patients. | 2010 Nov 10 |
|
A 64-week, multicenter, open-label study of aripiprazole effectiveness in the management of patients with schizophrenia or schizoaffective disorder in a general psychiatric outpatient setting. | 2010 Sep 17 |
Sample Use Guides
In Vivo Use Guide
Sources: http://www.adasuve.com/PDF/AdasuvePI.pdf http://www.accessdata.fda.gov/drugsatfda_docs/label/2012/022549s000lbl.pdf
Curator's Comment: Loxitane (loxapine) capsules are prescribed for schizophrenia in dosage 10 mg twice daily (initial dose, orally)
http://www.rxlist.com/loxitane-drug/indications-dosage.htm
Adasuve (loxapine inhalation powder), 10 mg by oral inhalation
Route of Administration:
Respiratory
Substance Class |
Chemical
Created
by
admin
on
Edited
Fri Dec 16 17:32:14 UTC 2022
by
admin
on
Fri Dec 16 17:32:14 UTC 2022
|
Record UNII |
X59SG0MRYU
|
Record Status |
Validated (UNII)
|
Record Version |
|
-
Download
Name | Type | Language | ||
---|---|---|---|---|
|
Official Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Code | English | ||
|
Code | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Code | English | ||
|
Common Name | English | ||
|
Brand Name | English |
Classification Tree | Code System | Code | ||
---|---|---|---|---|
|
NCI_THESAURUS |
C29710
Created by
admin on Fri Dec 16 17:32:14 UTC 2022 , Edited by admin on Fri Dec 16 17:32:14 UTC 2022
|
Code System | Code | Type | Description | ||
---|---|---|---|---|---|
|
M6915
Created by
admin on Fri Dec 16 17:32:14 UTC 2022 , Edited by admin on Fri Dec 16 17:32:14 UTC 2022
|
PRIMARY | Merck Index | ||
|
1370702
Created by
admin on Fri Dec 16 17:32:15 UTC 2022 , Edited by admin on Fri Dec 16 17:32:15 UTC 2022
|
PRIMARY | |||
|
248-682-0
Created by
admin on Fri Dec 16 17:32:14 UTC 2022 , Edited by admin on Fri Dec 16 17:32:14 UTC 2022
|
PRIMARY | |||
|
DTXSID3045227
Created by
admin on Fri Dec 16 17:32:14 UTC 2022 , Edited by admin on Fri Dec 16 17:32:14 UTC 2022
|
PRIMARY | |||
|
SUB02977MIG
Created by
admin on Fri Dec 16 17:32:14 UTC 2022 , Edited by admin on Fri Dec 16 17:32:14 UTC 2022
|
PRIMARY | |||
|
759578
Created by
admin on Fri Dec 16 17:32:15 UTC 2022 , Edited by admin on Fri Dec 16 17:32:15 UTC 2022
|
PRIMARY | |||
|
C47590
Created by
admin on Fri Dec 16 17:32:14 UTC 2022 , Edited by admin on Fri Dec 16 17:32:14 UTC 2022
|
PRIMARY | |||
|
27833-64-3
Created by
admin on Fri Dec 16 17:32:14 UTC 2022 , Edited by admin on Fri Dec 16 17:32:14 UTC 2022
|
PRIMARY | |||
|
X59SG0MRYU
Created by
admin on Fri Dec 16 17:32:14 UTC 2022 , Edited by admin on Fri Dec 16 17:32:14 UTC 2022
|
PRIMARY | |||
|
DBSALT001194
Created by
admin on Fri Dec 16 17:32:14 UTC 2022 , Edited by admin on Fri Dec 16 17:32:14 UTC 2022
|
PRIMARY | |||
|
71399
Created by
admin on Fri Dec 16 17:32:15 UTC 2022 , Edited by admin on Fri Dec 16 17:32:15 UTC 2022
|
PRIMARY | |||
|
CHEMBL831
Created by
admin on Fri Dec 16 17:32:14 UTC 2022 , Edited by admin on Fri Dec 16 17:32:14 UTC 2022
|
PRIMARY | |||
|
6476
Created by
admin on Fri Dec 16 17:32:15 UTC 2022 , Edited by admin on Fri Dec 16 17:32:15 UTC 2022
|
PRIMARY | RxNorm | ||
|
X59SG0MRYU
Created by
admin on Fri Dec 16 17:32:14 UTC 2022 , Edited by admin on Fri Dec 16 17:32:14 UTC 2022
|
PRIMARY |
Related Record | Type | Details | ||
---|---|---|---|---|
|
PARENT -> SALT/SOLVATE | |||
|
PARENT -> SALT/SOLVATE |
Related Record | Type | Details | ||
---|---|---|---|---|
|
IMPURITY -> PARENT |
CHROMATOGRAPHIC PURITY (HPLC/UV)
USP
|
||
|
IMPURITY -> PARENT |
CHROMATOGRAPHIC PURITY (HPLC/UV)
USP
|
||
|
IMPURITY -> PARENT |
CHROMATOGRAPHIC PURITY (HPLC/UV)
USP
|
Related Record | Type | Details | ||
---|---|---|---|---|
|
ACTIVE MOIETY |